A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs GSK 3377794 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Adaptimmune
- 10 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 15 Mar 2018 According to an Adaptimmune media release, data update from this and other study (NCT02992743: Myxoid/round cell liposarcoma) will be presented at an upcoming congress.
- 09 Nov 2017 According to an Adaptimmune media release, updated results of all cohorts of the study were presented at the annual CTOS meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History